Huang Huang

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar et al. · The Lancet Oncology · 2022 · 436 citations · Full text

Medicine, Clinical Sciences, Oncology +16

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Matthew Ku, Mark P. Hertzberg, Huiqiang Huang et al. · The Lancet · 2024 · 142 citations

Medicine, Hematology, Oncology +15

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Nancy L. Bartlett, Sarit Assouline, Pratyush Giri et al. · Blood Advances · 2023 · 93 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Ian W. Flinn, John G. Gribben, Martin J.S. Dyer et al. · Blood · 2019 · 72 citations · Full text

Medicine, Oncology, Pharmacology +14

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Sarit Assouline, Won Seog Kim, Laurie H. Sehn et al. · Blood · 2020 · 59 citations

Medicine, Oncology, Pharmacotherapy +12